Posted by Michael Wonder on 01 Apr 2026
Oculis announces EMA PRIME designation for privosegtor, advancing a potential first in class neuroprotective candidate for optic neuritis
31 March 2026 - Decision supported by positive Phase 2 ACUITY data showing substantial improvements in vision combined with anatomical and biological neuroprotective benefits in patients treated with Privosegtor.
Oculis today announced that its neuroprotective candidate Privosegtor has been granted Priority Medicines (PRIME) designation by the EMA for the treatment of optic neuritis, a rare, sight-threatening condition that is often a relapse of multiple sclerosis or its first clinical manifestation.
